First selective dual inhibitors of tau phosphorylation and beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer's disease

ACS Chemical Neuroscience

Volumn 5, Issue 12, 2014, Pages 1198-1202

  Mariano, Marica ^a   Schmitt, Christian ^a   Miralinaghi, Parisa ^a   Catto, Marco ^b   Hartmann, Rolf W ^a   Carotti, Angelo ^b   Engel, Matthias ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Alzheimer's disease; Dual inhibitors; Dyrk1A; Tau protein; amyloid

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; DUAL SPECIFICITY TYROSINE PHOSPHO REGULATED KINASE 1A; PHOSPHOTRANSFERASE INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG; DYRK KINASE; ENZYME INHIBITOR; GREEN FLUORESCENT PROTEIN; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; PHOSPHORYLATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ENZYME INHIBITORS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; TAU PROTEINS; TRANSFECTION;

EID: 84918526451     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn5001815     Document Type: Article

References (34)

1. Murphy, S. L., Xu, J., and Kochanek, K. D. (2013) Deaths: Final Data for 2010. National Vital Statistics Reports, Vol. 61, National Center for Health Statistics, Hyattsville, MD.
2. Ittner, L. M., and Götz, J. (2011) Amyloid-B and Tau - A Toxic Pas de Deux in Alzheimer 's Disease. Nat. Rev. Neurosci. 12, 65-72.
3. Hawkes, C. A., Carare, R. O., and Weller, R. O. (2014) Amyloid and Tau in the Brain in Sporadic Alzheimer's Disease: Defining the Chicken and the Egg. Acta Neuropathol. 127, 617-618.
4. Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M.-L., Yardin, C., and Terro, F. (2013) Tau Protein Kinases: Involvement in Alzheimer's Disease. Ageing Res. Rev. 12, 289-309.
5. Wisniewski, K. E., Wisniewski, H. M., and Wen, G. Y. (1985) Occurrence of Neuropathological Changes and Dementia of Alzheimer's Disease in Down's Syndrome. Ann. Neurol. 17, 278-282.
6. Wegiel, J., Dowjat, K., Kaczmarski, W., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur Kolecka, B., Wegiel, J., Silverman, W. P., Reisberg, B., Deleon, M., Wisniewski, T., Gong, C.-X., Liu, F., Adayev, T., Chen-Hwang, M.-C., and Hwang, Y.-W. (2008) The Role of Overexpressed DYRK1A Protein in the Early Onset of Neurofibrillary Degeneration in Down Syndrome. Acta Neuropathol. 116, 391-407.
7. Liu, F., Liang, Z., Wegiel, J., Hwang, Y.-W., Iqbal, K., Grundke-Iqbal, I., Ramakrishna, N., and Gong, C.-X. (2008) Overexpression of Dyrk1A Contributes to Neurofibrillary Degeneration in Down Syndrome. FASEB J. 22, 3224-3233.
8. Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., Tabara, Y., Miki, T., Akatsu, H., Kosaka, K., Funakoshi, E., Nishitomi, K., Sakaguchi, G., Kato, A., Hattori, H., Uema, T., and Takeda, M. (2007) The DYRK1A Gene, Encoded in Chromosome 21 Down Syndrome Critical Region, Bridges between Beta-Amyloid Production and Tau Phosphorylation in Alzheimer Disease. Hum. Mol. Genet. 16, 15-23.
9. Park, J., Yang, E. J., Yoon, J. H., and Chung, K. C. (2007) Dyrk1A Overexpression in Immortalized Hippocampal Cells Produces the Neuropathological Features of Down Syndrome. Mol. Cell. Neurosci. 36, 270-279.
10. Tejedor, F. J., and Hämmerle, B. (2011) MNB/DYRK1A as a Multiple Regulator of Neuronal Development. FEBS J. 278, 223-235.
11. Larson, M. E., Sherman, M. A., Greimel, S., Kuskowski, M., Schneider, J. A., Bennett, D. A., and Lesné, S. E. (2012) Soluble A-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology. J. Neurosci. 32, 10253-10266.
12. Ferrer, I., Barrachina, M., Puig, B., Martínez de Lagrán, M., Martí, E., Avila, J., and Dierssen, M. (2005) Constitutive Dyrk1A Is Abnormally Expressed in Alzheimer Disease, Down Syndrome, Pick Disease, and Related Transgenic Models. Neurobiol. Dis. 20, 392-400.
13. Roher, A. E., Lowenson, J. D., Clarke, S., Woods, A. S., Cotter, R. J., Gowing, E., and Ball, M. J. (1993) Beta-Amyloid-(1-42) Is a Major Component of Cerebrovascular Amyloid Deposits: Implications for the Pathology of Alzheimer Disease. Proc. Natl. Acad. Sci. U.S.A. 90, 10836-10840.
14. Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., and Selkoe, D. J. (1996) Sequence of Deposition of Heterogeneous Amyloid Beta-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation. Neurobiol. Dis. 3, 16-32.
15. Anighoro, A., Bajorath, J., and Rastelli, G. (2014) Polypharmacology: Challenges and Opportunities in Drug Discovery. J. Med. Chem., DOI: 10.1021/jm5006463.
16. Rizzo, S., Rivière, C., Piazzi, L., Bisi, A., Gobbi, S., Bartolini, M., Andrisano, V., Morroni, F., Tarozzi, A., Monti, J.-P., and Rampa, A. (2008) Benzofuran-Based Hybrid Compounds for the Inhibition of Cholinesterase Activity, Beta Amyloid Aggregation, and Abeta Neurotoxicity. J. Med. Chem. 51, 2883-2886.
17. Brogi, S., Butini, S., Maramai, S., Colombo, R., Verga, L., Lanni, C., De Lorenzi, E., Lamponi, S., Andreassi, M., Bartolini, M., Andrisano, V., Novellino, E., Campiani, G., Brindisi, M., and Gemma, S. (2014) Disease-Modifying Anti- Alzheimer's Drugs: Inhibitors of Human Cholinesterases Interfering with β-Amyloid Aggregation. CNS Neurosci. Ther. 20, 624-632.
18. Catto, M., Berezin, A. A., Lo Re, D., Loizou, G., Demetriades, M., De Stradis, A., Campagna, F., Koutentis, P. A., and Carotti, A. (2012) Design, Synthesis and Biological Evaluation of Benzo[e]-[1,2,4]triazin-7(1H)-one and [1,2,4]-Triazino[5,6,1-Jk]carbazol-6-one Derivatives as Dual Inhibitors of Beta-Amyloid Aggregation and Acetyl/butyryl Cholinesterase. Eur. J. Med. Chem. 58, 84-97.
19. Rook, Y., Schmidtke, K.-U., Gaube, F., Schepmann, D., Wünsch, B., Heilmann, J., Lehmann, J., and Winckler, T. (2010) Bivalent Beta-Carbolines as Potential Multitarget Anti-Alzheimer Agents. J. Med. Chem. 53, 3611-3617.
20. Calcul, L., Zhang, B., Jinwal, U. K., Dickey, C. A., and Baker, B. J. (2012) Natural Products as a Rich Source of Tau-Targeting Drugs for Alzheimer's Disease. Future Med. Chem. 4, 1751-1761.
21. Chandra, R., Kung, M.-P., and Kung, H. F. (2006) Design, Synthesis, and Structure-Activity Relationship of Novel Thiophene Derivatives for Beta-Amyloid Plaque Imaging. Bioorg. Med. Chem. Lett. 16, 1350-1352.
22. Schmitt, C., Kail, D., Mariano, M., Empting, M., Weber, N., Paul, T., Hartmann, R. W., and Engel, M. (2014) Design and Synthesis of a Library of Lead-like 2,4-Bisheterocyclic Substituted Thiophenes as Selective Dyrk/Clk Inhibitors. PLoS One 9, e87851.
23. Miralinaghi, P., Schmitt, C., Hartmann, R. W., Frotscher, M., and Engel, M. (2014) 6-Hydroxybenzothiophene Ketones: Potent Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1) Owing to Favorable Molecule Geometry and Conformational Preorganization. ChemMedChem, DOI: 10.1002/cmdc.201402050.
24. Porat, Y., Abramowitz, A., and Gazit, E. (2006) Inhibition of Amyloid Fibril Formation by Polyphenols: Structural Similarity and Aromatic Interactions as a Common Inhibition Mechanism. Chem. Biol. Drug Des. 67, 27-37.
25. Frost, D., Meechoovet, B., Wang, T., Gately, S., Giorgetti, M., Shcherbakova, I., and Dunckley, T. (2011) B-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites. PLoS One 6, e19264.
26. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., and Cohen, P. (2007) The Selectivity of Protein Kinase Inhibitors: A Further Update. Biochem. J. 408, 297-315.
27. Schmitt, C., Miralinaghi, P., Mariano, M., Hartmann, R. W., and Engel, M. (2014) Hydroxybenzothiophene Ketones Are Efficient Pre-mRNA Splicing Modulators Due to Dual Inhibition of Dyrk1A and Clk1/4. ACS Med. Chem. Lett. 5, 963-967.
28. Hartmann, A. M., Rujescu, D., Giannakouros, T., Nikolakaki, E., Goedert, M., Mandelkow, E. M., Gao, Q. S., Andreadis, A., and Stamm, S. (2001) Regulation of Alternative Splicing of Human Tau Exon 10 by Phosphorylation of Splicing Factors. Mol. Cell. Neurosci. 18, 80-90.
29. Yin, X., Jin, N., Gu, J., Shi, J., Zhou, J., Gong, C.-X., Iqbal, K., Grundke-Iqbal, I., and Liu, F. (2012) Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (Dyrk1A) Modulates Serine/arginine-Rich Protein 55 (SRp55)-Promoted Tau Exon 10 Inclusion. J. Biol. Chem. 287, 30497-30506.
30. Aggarwal, B. B., and Sung, B. (2009) Pharmacological Basis for the Role of Curcumin in Chronic Diseases: An Age-Old Spice with Modern Targets. Trends Pharmacol. Sci. 30, 85-94.
31. Bey, E., Marchais-Oberwinkler, S., Werth, R., Negri, M., Al-Soud, Y. A., Kruchten, P., Oster, A., Frotscher, M., Birk, B., and Hartmann, R. W. (2008) Design, Synthesis, Biological Evaluation and Pharmacokinetics of Bis(hydroxyphenyl) Substituted Azoles, Thiophenes, Benzenes, and Aza-Benzenes as Potent and Selective Nonsteroidal Inhibitors of 17beta-Hydroxysteroid Dehydrogenase Type 1 (17beta-HSD1). J. Med. Chem. 51, 6725-6739.
32. Bey, E., Marchais-Oberwinkler, S., Negri, M., Kruchten, P., Oster, A., Klein, T., Spadaro, A., Werth, R., Frotscher, M., Birk, B., and Hartmann, R. W. (2009) New Insights into the SAR and Binding Modes of Bis(hydroxyphenyl)thiophenes and -Benzenes: Influence of Additional Substituents on 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1) Inhibitory Activity and Selectivity. J. Med. Chem. 52, 6724-6743.
33. Flaherty, D. P., Kiyota, T., Dong, Y., Ikezu, T., and Vennerstrom, J. L. (2010) Phenolic Bis-Styrylbenzenes as β-Amyloid Binding Ligands and Free Radical Scavengers. J. Med. Chem. 53, 7992-7999.
34. Hirohata, M., Ono, K., Morinaga, A., and Yamada, M. (2008) Non-Steroidal Anti-Inflammatory Drugs Have Potent Anti-Fibrillogenic and Fibril-Destabilizing Effects for Alpha-Synuclein Fibrils in Vitro. Neuropharmacology 54, 620-627.